A 2-year-old girl with Diphyllobothrium nihonkaiense infection treated with oral praziquantel and a laxative

Atsushi Fujita1, Makoto Migita, Takahiro Ueda

  • 1Department of Pediatrics, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan. bxl02761@nms.ac.jp

Insights

This case study details a successful treatment for Diphyllobothrium nihonkaiense infection in a young child. The treatment involved oral praziquantel and a laxative, highlighting effective pediatric tapeworm management.

Area of Science:

  • Parasitology
  • Pediatric Infectious Diseases
  • Gastroenterology

Background:

  • Diphyllobothrium nihonkaiense is a tapeworm that can cause infection in humans.
  • Pediatric tapeworm infections require careful consideration for treatment and supportive care.

Observation:

  • A 2-year-old Japanese girl presented with Diphyllobothrium nihonkaiense infection.
  • Standard treatment protocols may involve oral praziquantel or duodenal intubation with contrast medium.

Findings:

  • The patient was successfully treated with oral praziquantel and a laxative.
  • This approach proved effective for managing Diphyllobothrium nihonkaiense infection in early childhood.

Implications:

  • Early childhood tapeworm infections can be managed effectively with standard antiparasitic medication and laxatives.
  • This case underscores the importance of timely diagnosis and appropriate treatment in pediatric patients.
  • Further research may explore optimal supportive care strategies alongside praziquantel for pediatric tapeworm infections.

Related Concept Videos

Anthelminthic Agents01:15

Anthelminthic Agents

Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
Giardiasis01:12

Giardiasis

Giardiasis is a globally prevalent intestinal infection caused by the protozoan parasite Giardia duodenalis (also known as G. lamblia or G. intestinalis). This flagellated protozoan is the most frequently identified intestinal parasite in the United States and worldwide. Transmission primarily occurs via the fecal-oral route, with infection arising from ingestion of water or food contaminated with cysts. Individuals in low-resource settings, international travelers, outdoor enthusiasts, daycare...
Amebiasis01:28

Amebiasis

Entamoeba histolytica, a protozoan parasite, is responsible for intestinal and extraintestinal amebiasis. Though a significant proportion of infections remain asymptomatic, approximately 50 million individuals annually are estimated to present with clinical disease, resulting in up to 100,000 deaths globally. The disease burden is disproportionately high in regions with lower socioeconomic status, such as parts of India, Africa, Mexico, and Latin America.Etiology and TransmissionThe infective...
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Antiprotozoal Agents01:21

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...
Drugs Affecting GI Tract Motility: Other Laxatives01:20

Drugs Affecting GI Tract Motility: Other Laxatives

Laxatives are primarily used to alleviate constipation, a common gastrointestinal disorder characterized by infrequent bowel movements and difficulty passing stools. They work by various mechanisms to increase the volume or frequency of bowel movements. The primary modes of action of laxatives include increasing stool bulk, softening the stool, stimulating intestinal motility, and osmotically drawing water into the intestines.
Osmotic or saline laxatives, like magnesium hydroxide or milk of...